Today on Pharmaceutical Processing
Catalent lays off workers, expands clinical supply facility in Shanghai
Contract manufacturing giant Catalent has wrapped up the expansion of a clinical supply facility in the Waigaoqiao Free Trade Zone (FTZ) in Shanghai, China. The company is also cutting 400 temporary and full-time workers in Bloomington, Indiana and more than 210 workers in Texas and Maryland. In a statement from Bloomington, Indiana Mayor John Hamilton blames the…
FDA yanks EUA for Lilly’s bebtelovimab COVID-19 antibody
The FDA has pulled the emergency use authorization (EUA) for bebtelovimab, the monoclonal antibody from Eli Lilly (NYSE:LLY), because it no longer adequately protects against the BQ.1 and BQ.1.1 omicron subvariants. In late November, the BQ.1 variant was responsible for 27.9% of U.S. COVID-19 infections, according to CDC. The BQ.1.1 variant represented 29.4% of infections. Meanwhile,…
Sponsored Content See More >
A new way to access scientific papers?Losing university access doesn’t mean losing access to articles anymore By DeepDyve Digital Library Team Many researchers are surprised to…
Anti-idiotype Antibodies: A Powerful Weapon for PK/ADA AssaysBy Sino Biological Therapeutic monoclonal antibodies have emerged as the fastest-growing class of therapeutics since the mid-1980s from the increasing…
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Regulatory See More >
Fresenius Kabi launches gadoterate meglumine injection
Fresenius Kabi has begun selling gadoterate meglumine injection, USP, a bioequivalent and therapeutic equivalent substitute for Guerbet’s contrast agent Dotarem. The product launch is the second contrast agent Fresenius Kabi has introduced in the U.S. this year. The Kale Zurich, Illinois–based company launched iodixanol injection, USP, in July during a nationwide shortage. Radiologists use contrast agents…
Facility See More >
Pfizer to invest billions in plants in Europe
Pharma giant Pfizer (NYSE:PFE) plans to spend more than $2.5 billion in facilities in Belgium and Ireland as it looks to diversify its product portfolio, according to Reuters. In 2021, Pfizer generated $36.9 billion in sales from the Comirnaty COVID-19 vaccine. The company projects its COVID-19 vaccine to rake in $34 billion in 2022, but COVID-related sales…
Supply Chain See More >
GE HealthCare investing $80M in contrast media ingredients plant in Norway
GE HealthCare today announced it is investing $80 million to expand contrast media production capacity in Norway. The investment will go toward increasing manufacturing capacity by 30% at its active pharmaceutical ingredients site in Lindesnes, Norway. As a result, the investment will create around 100 new jobs. GE HealthCare officials have committed to addressing the…
Cardinal Health beats The Street in Q1 — with pharma sales up 15%
Fujifilm establishing cell culture subsidiary in Korea
Actylis launches with focus on raw materials and performance ingredients for life sciences and specialty chemicals
U.S. government makes an additional 442,000 monkeypox vaccine doses available
Recalls See More >
Baxter issues Class 1 recall of Clearlink Basic Solution Sets with Duovent
The FDA has classified a recall of a Baxter Healthcare product used to deliver hazardous drugs such as chemotherapeutic agents Class 1, indicating that it could cause serious adverse health consequences or death. The recall covers all lots with product code 2R8403 distributed from October 14, 2020 to June 30, 2022. There are Baxter announced…
